Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-09-20
2009-12-15
Shukla, Ram R (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S145100, C435S810000, C530S387300
Reexamination Certificate
active
07632500
ABSTRACT:
In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.
REFERENCES:
patent: 4678772 (1987-07-01), Segal et al.
patent: 4835142 (1989-05-01), Suzuki et al.
patent: 4871740 (1989-10-01), Kurono et al.
patent: 5229378 (1993-07-01), Ogata et al.
patent: 5425948 (1995-06-01), Olivieri
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5594114 (1997-01-01), Goodearl et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5852174 (1998-12-01), Vlassara et al.
patent: 5864018 (1999-01-01), Morser et al.
patent: 6171779 (2001-01-01), Chada et al.
patent: 6177077 (2001-01-01), Tobinick
patent: 6303321 (2001-10-01), Tracey et al.
patent: 6323329 (2001-11-01), Bullerdiek
patent: 6329339 (2001-12-01), Pompei et al.
patent: 6448223 (2002-09-01), Tracey et al.
patent: 6468533 (2002-10-01), Tracey et al.
patent: 6468555 (2002-10-01), Nakamura
patent: 6677321 (2004-01-01), Levin
patent: 6720472 (2004-04-01), Chada et al.
patent: 6822078 (2004-11-01), Ozaki et al.
patent: 7060504 (2006-06-01), Tracey et al.
patent: 7097838 (2006-08-01), Tracey et al.
patent: 7151082 (2006-12-01), Tracey et al.
patent: 7192917 (2007-03-01), Tracey et al.
patent: 7220723 (2007-05-01), Tracey et al.
patent: 7288250 (2007-10-01), Newman, et al.
patent: 7304034 (2007-12-01), Tracey et al.
patent: 7537908 (2009-05-01), Tracey et al.
patent: 2002/0009749 (2002-01-01), Ozaki et al.
patent: 2002/0122799 (2002-09-01), Stern et al.
patent: 2002/0193432 (2002-12-01), Mjalli et al.
patent: 2003/0017155 (2003-01-01), Tracey et al.
patent: 2003/0027260 (2003-02-01), Goddard et al.
patent: 2003/0032090 (2003-02-01), Hardiman et al.
patent: 2003/0032674 (2003-02-01), Hwang
patent: 2003/0060410 (2003-03-01), Tracey et al.
patent: 2003/0113323 (2003-06-01), Tracey et al.
patent: 2003/0143194 (2003-07-01), Tracey et al.
patent: 2004/0005316 (2004-01-01), Tracey et al.
patent: 2004/0120953 (2004-06-01), Tracey et al.
patent: 2004/0141948 (2004-07-01), O'Keefe
patent: 2006/0240019 (2006-10-01), Tracey et al.
patent: 2007/0238640 (2007-10-01), Tracey et al.
patent: 2008/0167234 (2008-07-01), Tracey et al.
patent: 2008/0214454 (2008-09-01), Tracey et al.
patent: 2009/0148453 (2009-06-01), Newman et al.
patent: 0 552 439 (1993-07-01), None
patent: 1 079 849 (2002-01-01), None
patent: 1 757 937 (2007-02-01), None
patent: 2137125 (1999-12-01), None
patent: 62-166897 (1987-07-01), None
patent: 10 082788 (1998-03-01), None
patent: 2003-096099 (2003-04-01), None
patent: 2004 523579 (2004-08-01), None
patent: WO 96/25493 (1996-08-01), None
patent: WO 97/23611 (1997-07-01), None
patent: WO 98/50547 (1998-11-01), None
patent: WO 99/20756 (1999-04-01), None
patent: WO 99/20756 (1999-04-01), None
patent: WO 99/59609 (1999-11-01), None
patent: WO 00/20621 (2000-04-01), None
patent: WO 00/47104 (2000-08-01), None
patent: WO 00/55174 (2000-09-01), None
patent: WO 00/75358 (2000-12-01), None
patent: WO 01/72993 (2001-04-01), None
patent: WO 01/36488 (2001-05-01), None
patent: WO 01/55386 (2001-08-01), None
patent: WO 01/75067 (2001-10-01), None
patent: WO 01/90151 (2001-11-01), None
patent: WO 01/99210 (2001-12-01), None
patent: WO 02/069965 (2002-09-01), None
patent: WO 02/070007 (2002-09-01), None
patent: WO 02/074301 (2002-09-01), None
patent: WO 02/074337 (2002-09-01), None
patent: WO 02/089743 (2002-11-01), None
patent: WO 02/090520 (2002-11-01), None
patent: WO 02/092004 (2002-11-01), None
patent: WO 03/022296 (2003-03-01), None
patent: WO 03/075921 (2003-09-01), None
patent: WO 2004/004763 (2004-01-01), None
patent: WO 2004/046345 (2004-06-01), None
patent: WO 2005/026209 (2005-03-01), None
patent: WO 2006/024547 (2006-03-01), None
patent: WO 2007/011606 (2007-01-01), None
patent: WO 2008/076758 (2008-06-01), None
Abeyama, K., et al., “The N-terminal Domain of Thrombomodulin Sequesters High-Mobility Group -B1 Protein, a Novel Antiinflammatory Mechanism,”J. Clinical Investigation115(5):1267-1274, (May 2005).
Aderem, A. and Ulevitch, R.J., “Toll-Like Receptors in the Induction of the Innate Immune Response,”Nature, 406:782-787 (2000).
Akamatsu, H., et al., “Mechanism of Anti-Inflammatory Action of Glycyrrhizin: Effect on Neutrophil Functions Including Reactive Oxygen Species Generation,”Planta Med.57(2):119-121 (1991).
Alleva, L. M., et al. , “High Mobility Group Box 1 (HMGB1) Protein: Possible Amplification Signal in the Pathogenesis of Falciparum Malaria,”Trans. R. Soc. Trop. Med. Hyg., 99:171-174 (2005).
Andersson, U. and Erlandsson-Harris, H., “HMGB1 is a potent trigger of arthritis,”J. Internal Med., 255:344-350 (2004).
Andersson, U., et al., “HMGB1 as a DNA-ginding Cytokine,”J. Leukocyte Biol.72:1084-1091 (2002).
Attwood, T.K., “The Babel of Bioinformatics,”Science, 290:471-473 (2000).
Azimov, M. M., et al., “Pharmacological Study of the Anti-Inflammatory Agent Glyderinine,”Farmakol. Toksikol.51(4):90-93 (1988). English Abstract.
Beutler, E., et al., “Synergy Between TLR2 and TLR4: A Safety Mechanism,”Blood Cells, Mol. Dis., 27(4):728-730 (2001).
Bianchi, E.V., et al., “Supression of ProinflammatoryCytokines in Monocytes by a Tetravalent Guanylhydrazone,”J. Exp. Med183:927-936 (Mar. 1996).
Bianchi, M.E. and Manfredi, A.A., “High-Mobility Group Box 1 (HMGB1) Protein at the Crossroads Between Innate and Adaptive Immunity,”Immunological Reviews220:35-46 (2007).
Bustin M., “Regulation of DNA-Dependent Activities by the functional Motifs of the High-Mobility-Group Chromosomal Proteins,”Mol. Cell. Biol.19(8):5237-46 (1999).
Cãbart, P., et al., “Differential Expression of Nuclear HMG1, HMG2 Proteins and H10 Histone in Various Blood Cells,”Cell Biochemistry and Function13:125-133 (1995).
Czura, C.J., et al., “HMGB1 in the Immunology of Sepsis (not septic shock) and Arthritis,”Advances in Immunology84:181-200 (2004).
Dallman, M.J., “Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult,”Curr Opin Immunol, 7:632-638 (1995).
Dorland's Illustrated Medical Dictionary, 28th ed. (Philadelphia, W.B. Saunders Co.), 1994, p. 269.
Dunn, M.D., Ph.D., D.L., “Role of Endotoxin and Host Cytokines in Spetic Shock,”Chest100(3):164S-168S (Sep. 1991 Supplement).
Fei, J., et al., “Study on High Mobility Group-1 Protein in Patients with Multiple Trauma,”Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 17(5):273-275 (2005).
Fiuza, C., et al. “Inflammation-Promoting Activity of HMGB1 on Human Microvascular Endothelial Cells,”Blood101(7): 2652-2660 (2003).
Friend, P.J., et al., “Phase I Study of an Engineered Agycosylated Humanized CD3 Antibody in Renal Transplant Rejection,”Transplantation, 68(11):1625-1626 (1999).
Goldstein, R.S., et al. “HMGB1 Detection in Patients with Cerebral and Myocardial Ischemia,” J. Invest. Med., 53(2): S387 (2005) (Abstract From Joint Annual Meeting of the Central-Society-for-Clinical-Research/Midwestern American-Federation-for-Medical-Research).
“High Mobility Group, (HMG) Chromosomal Proteins Nomenclature Home Page” [online] [retrieved on Nov. 7, 2005], retrieved from the Internet :< URL: http://www.informatics.jax.org/mgihome
omen/genefamilies/hmgfamily.shtml>.
Hori, O., et al., “The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin,”J. Biol. Chem., 270(43):25752-25761 (1995).
HSTAT, Health Services/Technology Assessment Test. AHRQ Evidence Reports, No. 83, “Effect of Su
Newman Walter
O'Keefe Theresa L.
Obar Robert A.
Qin Shixin
Cornerstone Therapeutics, Inc.
Hamilton Brook Smith & Reynolds P.C.
Shukla Ram R
Skelding Zachary
LandOfFree
Monoclonal antibodies against HMGB1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies against HMGB1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies against HMGB1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4067488